IL21R and neoplasm: IL21R (interleukin 21 receptor) knock-down may sensitize cells to anti-tumor therapy by targeting MMPs, and participate in tumor progression and metastasis in advanced breast cancer (Kim et al., 2014; Wang et al., 2015).